ArticleJournal of the American Heart Association2026
Increased Incidence of De Novo Malignancies Compared With Malignancy Recurrences in Survivors of Cancer Undergoing Heart Transplantation.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA proportion of cancer survivors (CS) with heart failure develop advanced heart failure. In select CS with advanced heart failure, heart transplantation (HT) remains the gold standard treatment. CS have been shown to have increased incidence of subsequent primary cancers (SPC). This study investigated the incidence and characteristics of SPC in CS undergoing HT at a high-volume HT center.
methodsA retrospective analysis of adult CS (age≥18) who underwent HT at Columbia University Irving Medical Center between January 1, 2000, and August 1, 2020, was conducted. Patients with nonmelanoma skin cancer were excluded. Kaplan-Meier analysis was used to measure cancer-free survival.
resultsOf 1332 consecutive patients undergoing HT at our institution between January 1, 2000, and August 1, 2020, 104 patients were CS (7.8%). CS had improved survival compared with the non-CS group, with a 5-, 10-, and 15-year survival of 89%, 70%, and 60% in the CS group compared with 78%, 64%, and 41% in the non-CS group. Twenty-two (21.2%) developed SPC at a median of 4 years (interquartile range, 3-7.75) posttransplant. Eighteen of 22 SPC (82%) were de novo malignancies, and 4 were recurrences.
conclusionsCS are 4 times more likely to have de novo malignancies unrelated to their primary malignancy rather than a recurrence. Despite the high rate of SPC, survival in this cohort was comparable to contemporary survival in HT patients. Further studies are required to understand optimal prevention and screening for SPC in CS undergoing HT beyond recommendations in the general population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.